US EditionPublished • loading... • Updated
GC Biopharma's Varicella Vaccine Strain 'MAV/06' Listed in WHO Position Paper
- GC Biopharma's varicella vaccine, BARYCELA Inj., is now recognized by the WHO with the inclusion of the MAV/06 strain, achieving equivalent status to Oka strain-based vaccines.
- The WHO endorsed the interchangeability of MAV/06 and Oka strains for use in two-dose immunization schedules.
- A Phase 3 clinical trial confirmed the immunogenicity and safety of MAV/06 for BARYCELA Inj., published in a peer-reviewed journal.
- MAV/06's inclusion in the WHO Position Paper strengthens global varicella vaccine supply and allows for strain substitution, thereby improving vaccination continuity.
Insights by Ground AI
63 Articles
63 Articles
Coverage Details
Total News Sources63
Leaning Left8Leaning Right9Center20Last UpdatedBias Distribution54% Center
Bias Distribution
- 54% of the sources are Center
54% Center
L 22%
C 54%
R 24%
Factuality
To view factuality data please Upgrade to Premium
